DY
TEVA icon

Dowling & Yahnke’s Teva Pharmaceuticals TEVA Stock Holding History

Dowling & Yahnke’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,104
Closed -$256K – 266
2015
Q1 		$256K Buy
+4,104
New +$239K 0.03% 233

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.48B AUM 18.36% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

Dowling & Yahnke's TEVA Position: Q2 2015 in Review

Dowling & Yahnke sold out of Teva Pharmaceuticals (TEVA) in Q2 2015, closing a stake of 4,104 shares — an estimated $256K sold.

Dowling & Yahnke first reported a position in TEVA in Q1 2015 and held it in 1 quarter. The position peaked at $256K in Q1 2015. 819 funds tracked by Wall St. Rank hold TEVA as of Q2 2015.

  • Dowling & Yahnke reported no remaining Teva Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Dowling & Yahnke sold 4,104 Teva Pharmaceuticals shares in Q2 2015, an estimated $256K.
  • Dowling & Yahnke first reported a position in Teva Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Dowling & Yahnke's Teva Pharmaceuticals position peaked at $256K in Q1 2015.
  • 819 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2015.

Based on Dowling & Yahnke's 13F filing for Q2 2015, filed 22 Jul 2015.